Galectin Therapeutics Inc. (GALT)
GALT moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How GALT actually reacts to news — the realized, point-in-time move the market made, measured across 309 labeled events over the last three years with zero look-ahead.
GALT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 43% | 299 |
| 30-min | 0.00% | 50% | 309 |
| 60-min | 0.00% | 49% | 309 |
| to close | 0.00% | 48% | 306 |
| Middle 50% of GALT reactions | -1.46% to +1.73% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 309 |
Half of all Galectin Therapeutics Inc. news events land between -1.46% and +1.73% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How GALT reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 10 | -0.14% | 50% | +0.57% |
| Analyst downgrades | 10 | +0.67% | 60% | -2.83% |
| Rating reiterations | 19 | +1.24% | 74% | +1.81% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how GALT ranks against every other measured name →
That’s how GALT usually reacts — get an email when it moves on news →Email me when GALT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to GALT's baseline. Nothing else.
Recent GALT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form ARS GALECTIN THERAPEUTICS For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.26% | -3.91% | |
| Form DEF 14A GALECTIN THERAPEUTICS For: Dec 03 | SEC filing · Form DEF | SEC EDGAR | -0.26% | -3.91% | |
| Form DEFA14A GALECTIN THERAPEUTICS | SEC filing · Form DEFA14A | SEC EDGAR | -0.26% | -3.91% | |
| Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026 | Press release | GlobeNewswire | -2.67% | +0.27% | |
| Form PRE 14A GALECTIN THERAPEUTICS For: Dec 03 | SEC filing · Form PRE | SEC EDGAR | -0.38% | -0.38% | |
| Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference | Press release | GlobeNewswire | -1.75% | -2.50% | |
| Form 10-Q GALECTIN THERAPEUTICS For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -4.57% | -1.71% | |
| Form 8-K GALECTIN THERAPEUTICS For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | -4.57% | -1.71% | |
| Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -4.57% | -1.71% | |
| Form 8-K GALECTIN THERAPEUTICS For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | +3.38% | +0.84% | |
| Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet | Press release | GlobeNewswire | +3.38% | +0.84% | |
| Form 8-K GALECTIN THERAPEUTICS For: Jun 23 | SEC filing · Form 8-K | SEC EDGAR | +7.93% | +15.13% | |
| Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension | Press release | GlobeNewswire | +7.93% | +15.13% | |
| Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis | Press release | GlobeNewswire | +0.18% | -4.25% | |
| Form 10-Q GALECTIN THERAPEUTICS For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.91% | -8.05% | |
| Form 8-K GALECTIN THERAPEUTICS For: May 15 | SEC filing · Form 8-K | SEC EDGAR | -1.91% | -8.05% | |
| Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -1.91% | -8.05% | |
| Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology | Press release | GlobeNewswire | +1.20% | +5.74% | |
| Form EFFECT GALECTIN THERAPEUTICS | SEC filing · Form EFFECT | SEC EDGAR | -0.44% | +2.62% | |
| Form 10-K GALECTIN THERAPEUTICS For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +2.35% | +9.41% | |
| Form 8-K GALECTIN THERAPEUTICS For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | +2.35% | +9.41% | |
| Form S-3 GALECTIN THERAPEUTICS | SEC filing · Form S-3 | SEC EDGAR | +1.08% | -3.60% | |
| Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +2.35% | +9.41% | |
| Form 8-K GALECTIN THERAPEUTICS For: Mar 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D. | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET | Press release | GlobeNewswire | +0.64% | -4.18% | |
| Form 8-K GALECTIN THERAPEUTICS For: Jan 16 | SEC filing · Form 8-K | SEC EDGAR | -0.90% | +11.36% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Galectin Therapeutics Inc. (GALT) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.81% | +2.69% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Galectin Therapeutics Inc. (GALT) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.00% | -1.60% | |
| Form 8-K GALECTIN THERAPEUTICS For: Jan 10 | SEC filing · Form 8-K | SEC EDGAR | -1.56% | -4.06% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Galectin Therapeutics Inc. (GALT) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.96% | +0.96% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Galectin Therapeutics Inc. (GALT) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.14% | -7.91% | |
| Galectin Therapeutics Inc. (GALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.13% | -8.73% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Galectin Therapeutics Inc. (GALT) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | -1.48% | -4.43% | |
| Galectin Therapeutics Inc. (GALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.23% | -5.81% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Galectin Therapeutics Inc. (GALT) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.59% | -3.57% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Galectin Therapeutics Inc. (GALT) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.50% | +3.35% | |
| Form 8-K GALECTIN THERAPEUTICS For: Dec 19 | SEC filing · Form 8-K | SEC EDGAR | -8.84% | -5.60% | |
| Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027 | Press release | GlobeNewswire | -8.84% | -5.60% | |
| Form 8-K GALECTIN THERAPEUTICS For: Dec 03 | SEC filing · Form 8-K | SEC EDGAR | +3.16% | +5.80% | |
| Form 8-K GALECTIN THERAPEUTICS For: Dec 03 | SEC filing · Form 8-K | SEC EDGAR | — | +2.43% | |
| Form 10-Q GALECTIN THERAPEUTICS For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.94% | +8.04% | |
| Form 8-K GALECTIN THERAPEUTICS For: Nov 14 | SEC filing · Form 8-K | SEC EDGAR | +2.94% | +8.04% | |
| Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update | Press release | GlobeNewswire | +2.94% | +8.04% | |
| Form 8-K GALECTIN THERAPEUTICS For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | +5.65% | -3.70% | |
| Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting | Press release | GlobeNewswire | +5.65% | -3.70% | |
| Form ARS GALECTIN THERAPEUTICS For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.57% | -7.92% | |
| Form DEF 14A GALECTIN THERAPEUTICS For: Dec 03 | SEC filing · Form DEF | SEC EDGAR | -0.57% | -7.92% | |
| Form DEFA14A GALECTIN THERAPEUTICS | SEC filing · Form DEFA14A | SEC EDGAR | -0.57% | -7.92% | |
| Galectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor Conference | Press release | GlobeNewswire | +0.20% | +0.59% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the GALT section they belong to.
Where else GALT is measured.
GALT earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| NeuroOne Medical Technologies Corporation (NMTC) | 310 | -0.19% | 41% |
| SI-BONE, Inc. (SIBN) | 310 | +0.14% | 56% |
| MENLO THERAPEUTICS INC COMMON (MNLO) | 308 | 0.00% | 49% |
| Syros Pharmaceuticals, Inc. (SYRS) | 307 | +0.51% | 55% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Galectin Therapeutics Inc.'s median reaction calculated?
Every labeled GALT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 309 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of GALT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does GALT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.